| Drug Name: | Darifenacin (133099-04-4) |
|---|---|
| PubChem ID: | 444031 |
| SMILES: | C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5 |
| InchiKey: | HXGBXQDTNZMWGS-RUZDIDTESA-N |
| Therapeutic Category: | Cholinergic Agents, Cholinergic Antagonists, Muscarinic Antagonists, Neurotransmitter Agents, Urological Agents |
| Molecular Weight (dalton) | : | 426.56 |
| LogP | : | 3.9575 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 55.56 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Grapefruit Juice | Constipation | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
| Grapefruit Juice | Urinary Retention | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category